Laboratorio Reig Jofre, S.A. (BME:RJF)

Inozyme Pharma Income Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	336.02	341.37	317.95	274.21	239.87	233.76
Revenue Growth (YoY)	0.74%	7.36%	15.95%	14.32%	2.61%	13.57%
Cost of Revenue	145.17	147.92	141.06	119.12	96.9	94.93
Gross Profit	190.85	193.45	176.89	155.09	142.97	138.83
Selling, General & Admin	102.74	100.78	89.79	81.87	73.9	75.55
Other Operating Expenses	55.92	54.58	51.96	42.79	41.75	36.74
Operating Expenses	182.33	178.71	164.9	145.72	133.7	129.27
Operating Income	8.52	14.73	11.99	9.37	9.28	9.57
Interest Expense	-0.54	-1	-0.75	-0.69	-0.68	-0.68
Interest & Investment Income	0.29	0.29	0.06	0.1	0.05	0.03
Earnings From Equity Investments	0.1	-0.12	0.98	1.59	0.09	0.09
Currency Exchange Gain (Loss)	0.01	0.01	0.07	0.06	-0.36	0.07
Other Non Operating Income (Expenses)	0.31	0.29	-0.15	-0.7	-2.15	-2.29
EBT Excluding Unusual Items	8.68	14.2	12.21	9.74	6.23	6.79
Impairment of Goodwill	-1	-1	-	-0.4	-	-
Gain (Loss) on Sale of Assets	-1.38	-1.38	-0.72	-0.57	-0.44	-0.36
Asset Writedown	0.36	-	-1	-	0	-
Pretax Income	6.66	11.82	10.5	8.76	5.79	6.43
Income Tax Expense	0.21	1.36	1.1	0.66	0.71	0.76
Earnings From Continuing Operations	6.45	10.47	9.4	8.11	5.08	5.67
Minority Interest in Earnings	-0.09	-0.09	0.01	0	0.01	0.01
Net Income	6.37	10.38	9.41	8.11	5.09	5.67
Net Income to Common	6.37	10.38	9.41	8.11	5.09	5.67
Net Income Growth	-31.31%	10.37%	16.04%	59.21%	-10.23%	14.77%
Shares Outstanding (Basic)	-	80	80	79	78	77
Shares Outstanding (Diluted)	-	80	80	79	78	77
Shares Change (YoY)	-	-0.01%	1.50%	1.32%	1.13%	7.99%
EPS (Basic)	-	0.13	0.12	0.10	0.07	0.07
EPS (Diluted)	-	0.13	0.12	0.10	0.07	0.07
EPS Growth	-	10.37%	17.49%	52.89%	-6.56%	0.97%
Free Cash Flow	-	11.08	6.65	5.2	-4.73	6.75
Free Cash Flow Per Share	-	0.14	0.08	0.07	-0.06	0.09
Dividend Per Share	0.049	0.049	0.040	0.040	0.040	0.045
Dividend Growth	22.50%	22.50%	-	-	-11.11%	-
Gross Margin	56.80%	56.67%	55.63%	56.56%	59.60%	59.39%
Operating Margin	2.53%	4.32%	3.77%	3.42%	3.87%	4.09%
Profit Margin	1.89%	3.04%	2.96%	2.96%	2.12%	2.43%
Free Cash Flow Margin	-	3.25%	2.09%	1.90%	-1.97%	2.89%
EBITDA	22.66	31.1	28.3	22.56	20.36	20.32
EBITDA Margin	6.74%	9.11%	8.90%	8.23%	8.49%	8.69%
D&A For EBITDA	14.14	16.37	16.31	13.19	11.08	10.75
EBIT	8.52	14.73	11.99	9.37	9.28	9.57
EBIT Margin	2.53%	4.32%	3.77%	3.42%	3.87%	4.09%
Effective Tax Rate	3.08%	11.46%	10.47%	7.51%	12.31%	11.83%
Advertising Expenses	-	11.96	12.96	10.99	9	8.38

Updated Feb 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.